Literature DB >> 11024148

Functional importance of the coiled-coil of the Ebola virus glycoprotein.

S Watanabe1, A Takada, T Watanabe, H Ito, H Kida, Y Kawaoka.   

Abstract

Ebola virus contains a single glycoprotein (GP) that is responsible for receptor binding and membrane fusion and is proteolytically cleaved into disulfide-linked GP1 and GP2 subunits. The GP2 subunit possesses a coiled-coil motif, which plays an important role in the oligomerization and fusion activity of other viral GPs. To determine the functional significance of the coiled-coil motif of GP2, we examined the effects of peptides corresponding to the coiled-coil motif of GP2 on the infectivity of a mutant vesicular stomatitis virus (lacking the receptor-binding/fusion protein) pseudotyped with the Ebola virus GP. A peptide corresponding to the C-terminal helix reduced the infectivity of the pseudotyped virus. We next introduced alanine substitutions into hydrophobic residues in the coiled-coil motif to identify residues important for GP function. None of the substitutions affected GP oligomerization, but some mutations, two in the N-terminal helix and all in the C-terminal helix, reduced the ability of GP to confer infectivity to the mutant vesicular stomatitis virus without affecting the transport of GP to the cell surface, its incorporation into virions, and the production of virus particles. These results indicate that the coiled-coil motif of GP2 plays an important role in facilitating the entry of Ebola virus into host cells and that peptides corresponding to this region could act as efficient antiviral agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11024148      PMCID: PMC102058          DOI: 10.1128/jvi.74.21.10194-10201.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

Review 1.  HIV-1 entry inhibitors in the side pocket.

Authors:  J G Sodroski
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

2.  Side chain contributions to the stability of alpha-helical structure in peptides.

Authors:  P C Lyu; M I Liff; L A Marky; N R Kallenbach
Journal:  Science       Date:  1990-11-02       Impact factor: 47.728

3.  Glycosylation and oligomerization of the spike protein of Marburg virus.

Authors:  H Feldmann; C Will; M Schikore; W Slenczka; H D Klenk
Journal:  Virology       Date:  1991-05       Impact factor: 3.616

4.  The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses.

Authors:  V E Volchkov; V M Blinov; S V Netesov
Journal:  FEBS Lett       Date:  1992-07-06       Impact factor: 4.124

5.  Folding and function of a T4 lysozyme containing 10 consecutive alanines illustrate the redundancy of information in an amino acid sequence.

Authors:  D W Heinz; W A Baase; B W Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

6.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

7.  Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity.

Authors:  J W Dubay; S J Roberts; B Brody; E Hunter
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

8.  Mutational analysis of the putative fusion domain of Ebola virus glycoprotein.

Authors:  H Ito; S Watanabe; A Sanchez; M A Whitt; Y Kawaoka
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

9.  Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein.

Authors:  J Cao; L Bergeron; E Helseth; M Thali; H Repke; J Sodroski
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

10.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

View more
  67 in total

1.  Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.

Authors:  May S ElSherif; Catherine Brown; Donna MacKinnon-Cameron; Li Li; Trina Racine; Judie Alimonti; Thomas L Rudge; Carol Sabourin; Peter Silvera; Jay W Hooper; Steven A Kwilas; Nicole Kilgore; Christopher Badorrek; W Jay Ramsey; D Gray Heppner; Tracy Kemp; Thomas P Monath; Teresa Nowak; Shelly A McNeil; Joanne M Langley; Scott A Halperin
Journal:  CMAJ       Date:  2017-06-19       Impact factor: 8.262

2.  A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Authors:  Jason A Regules; John H Beigel; Kristopher M Paolino; Jocelyn Voell; Amy R Castellano; Zonghui Hu; Paula Muñoz; James E Moon; Richard C Ruck; Jason W Bennett; Patrick S Twomey; Ramiro L Gutiérrez; Shon A Remich; Holly R Hack; Meagan L Wisniewski; Matthew D Josleyn; Steven A Kwilas; Nicole Van Deusen; Olivier Tshiani Mbaya; Yan Zhou; Daphne A Stanley; Wang Jing; Kirsten S Smith; Meng Shi; Julie E Ledgerwood; Barney S Graham; Nancy J Sullivan; Linda L Jagodzinski; Sheila A Peel; Judie B Alimonti; Jay W Hooper; Peter M Silvera; Brian K Martin; Thomas P Monath; W Jay Ramsey; Charles J Link; H Clifford Lane; Nelson L Michael; Richard T Davey; Stephen J Thomas
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

3.  Spring-loaded heptad repeat residues regulate the expression and activation of paramyxovirus fusion protein.

Authors:  Laura E Luque; Charles J Russell
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

4.  Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway.

Authors:  Makoto Ujike; Hiroki Nishikawa; Akira Otaka; Naoki Yamamoto; Norio Yamamoto; Masao Matsuoka; Eiichi Kodama; Nobutaka Fujii; Fumihiro Taguchi
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 5.  Ebola virus pathogenesis: implications for vaccines and therapies.

Authors:  Nancy Sullivan; Zhi-Yong Yang; Gary J Nabel
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Inhibition of arenavirus infection by a glycoprotein-derived peptide with a novel mechanism.

Authors:  Jennifer S Spence; Lilia I Melnik; Hussain Badani; William C Wimley; Robert F Garry
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

7.  Influenza B virus BM2 protein is transported through the trans-Golgi network as an integral membrane protein.

Authors:  Shinji Watanabe; Masaki Imai; Yoshiro Ohara; Takato Odagiri
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding.

Authors:  Derek Dube; Matthew B Brecher; Sue E Delos; Sean C Rose; Edward W Park; Kathryn L Schornberg; Jens H Kuhn; Judith M White
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

9.  Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition.

Authors:  Osvaldo Martinez; Joshua Johnson; Balaji Manicassamy; Lijun Rong; Gene G Olinger; Lisa E Hensley; Christopher F Basler
Journal:  Cell Microbiol       Date:  2009-09-22       Impact factor: 3.715

10.  Coiled-coil domains in glycoproteins B and H are involved in human cytomegalovirus membrane fusion.

Authors:  Matthew Lopper; Teresa Compton
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.